Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arpan Acharya

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Antiviral Research|May 10, 2024
SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2Kabita Pandey, Arpan Acharya, Dhananjaya Pal, et al.
JCI Insight|February 4, 2025
IL-21 and anti-α4β7 dual therapy during ART promotes immunological and microbiome responses in SIV-infected macaquesSamuel D Johnson, Maria Pino, Arpan Acharya, et al.
Journal of Molecular Medicine (Berlin, Germany)|August 19, 2020
Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19)Omalla A Olwenyi, Shetty Ravi Dyavar, Arpan Acharya, et al.
Cells|September 16, 2020
Retinoic Acid Improves the Recovery of Replication-Competent Virus from Latent SIV Infected CellsOmalla A Olwenyi, Arpan Acharya, Nanda Kishore Routhu, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2021
Defining the Immune Responses for SARS-CoV-2-Human Macrophage InteractionsMai Abdelmoaty, Pravin Yeapuri, Jatin Machhi, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2021
Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-α/mTOR/BRD4 inhibitorArpan Acharya, Kabita Pandey, Michellie Thurman, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|September 16, 2022
Modular nanoarray vaccine for SARS-CoV-2Karen Zagorski, Kabita Pandey, Rajesh Rajaiah, et al.
Frontiers in Genetics|January 21, 2026
Genomic and ancestral variations linked to the development of post-acute sequelae of SARS-CoV-2 infection in Indian populationsPooja Umesh Shenoy, Hrushikesh Udupa, A I Ananthakrishnan, et al.
Scientific Reports|February 15, 2025
9-aminominocycline potentiates the efficacy of EIDD-1931 and PF-332 by targeting the papain like protease enzyme of SARS-CoV-2Kabita Pandey, Devin Shane M Lewis, Kyeongin Heo, et al.
The American Journal of Pathology|April 1, 2023
Inflammation-Associated Lung Tissue Remodeling and Fibrosis in Morphine-Dependent SIV-Infected MacaquesDivya T Chemparathy, Susmita Sil, Shannon Callen, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Antiviral Research|May 10, 2024
SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2Kabita Pandey, Arpan Acharya, Dhananjaya Pal, et al.
JCI Insight|February 4, 2025
IL-21 and anti-α4β7 dual therapy during ART promotes immunological and microbiome responses in SIV-infected macaquesSamuel D Johnson, Maria Pino, Arpan Acharya, et al.
Journal of Molecular Medicine (Berlin, Germany)|August 19, 2020
Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19)Omalla A Olwenyi, Shetty Ravi Dyavar, Arpan Acharya, et al.
Cells|September 16, 2020
Retinoic Acid Improves the Recovery of Replication-Competent Virus from Latent SIV Infected CellsOmalla A Olwenyi, Arpan Acharya, Nanda Kishore Routhu, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2021
Defining the Immune Responses for SARS-CoV-2-Human Macrophage InteractionsMai Abdelmoaty, Pravin Yeapuri, Jatin Machhi, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2021
Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-α/mTOR/BRD4 inhibitorArpan Acharya, Kabita Pandey, Michellie Thurman, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|September 16, 2022
Modular nanoarray vaccine for SARS-CoV-2Karen Zagorski, Kabita Pandey, Rajesh Rajaiah, et al.
Frontiers in Genetics|January 21, 2026
Genomic and ancestral variations linked to the development of post-acute sequelae of SARS-CoV-2 infection in Indian populationsPooja Umesh Shenoy, Hrushikesh Udupa, A I Ananthakrishnan, et al.
Scientific Reports|February 15, 2025
9-aminominocycline potentiates the efficacy of EIDD-1931 and PF-332 by targeting the papain like protease enzyme of SARS-CoV-2Kabita Pandey, Devin Shane M Lewis, Kyeongin Heo, et al.
The American Journal of Pathology|April 1, 2023
Inflammation-Associated Lung Tissue Remodeling and Fibrosis in Morphine-Dependent SIV-Infected MacaquesDivya T Chemparathy, Susmita Sil, Shannon Callen, et al.
Pageof 7